Systems and methods for the use of compounds from the Hofmeister series coupled with specific pH and temperature to provide rapid physico-chemical-managed killing of penicillin-resistant static and growing Gram-positive and Gram-negative vegetative bacteria. The systems and methods represent the more general physico-chemical enhancement of susceptibility for a wide range of pathological macromolecular targets to clinical management by establishing the reactivity of those targets to topically applied drugs or anti-toxins.
Figure 1

MRSA Log-Phase; PBS, pH 5.5; 1024 μg Cloxacillin, 22°C

Figure 2

MRSA Log-Phase; PBS pH 7.4; 512 μg Cloxacillin, 22°C
Figure 3

MRSA Log-Phase; SS; pH 7.4; 512μg Cloxacillin; 22°C

Figure 4

MRSA Log-Phase; SS; pH 5.5; 1024μg Cloxacillin; 22°C
Figure 5

MRSA Stat-Phase: SS; pH 7.4; 512ug Cloxacillin, 22°C

Figure 6

MRSA Stat-Phase: SS; pH 7.4; 1024ug Cloxacillin, 22°C
Figure 7

MRSA Staph-Phase, SS, pH 7.4; 2048ug Cloxacillin; 22°C

Figure 8

MRSA Staph-Phase, SS, pH 7.4; 4096ug Cloxacillin; 22°C
Figure 9

MRSA Stat-Phase; SS; pH 7.4; 4096ug Cloxacillin; 22°C

Figure 10

MRSA Log-Phase; SS; pH 7.4; 512ug Cloxacillin; 35°C
Figure 11
MRSA Log-Phase; SS; pH 7.4; 1024ug Cloxacillin; 35°C

Figure 12
MRSA Log-Phase; SS; pH 7.4; 2048ug Cloxacillin; 35°C
Figure 13

MRSA Log-Phase: SS; pH 7.4; 4096ug Cloxacillin; 35°C

Figure 14

MRSA Stat-Phase: SS; pH 7.4; 512ug Cloxacillin; 35°C
Figure 15

Figure 16

MRSA Stat-Phase; SS; pH 7.4; 1024ug Cloxacillin; 35°C

surviving fraction

minutes

10^-1

10^1

10^2

10^3

10^4

10^5

10^6

0 5 10 15 20 25 30 35 40 45 50 55 60 65
MRSA Stat-Phase: SS; pH 7.4; 4096ug Ciprofloxacin; 35°C

Figure 17

P. aeruginosa Log-Phase: PBS; pH 7.4; 22°C & 35°C

Figure 18
P. aeruginosa Log-Phase: SS; pH 7.4, 22°C & 35°C

Figure 19

P. aeruginosa Stal-Phase, SS; pH 7.4; 22°C & 35°C

Figure 20
**Figure 21**

P. aeruginosa Stat-Phase; SS: pH 7.4; 22°C & 35°C

**Figure 22**

P. aeruginosa Log-Phase; PBS: pH 7.4; 512µg Cloxacillin; 22°C
**Figure 23**

P. aeruginosa Log-Phase; PBS; pH 7.4; 1024 μg Ciprofloxacin; 22°C

**Figure 24**

P. aeruginosa Log-Phase; FBS; pH 7.4; 2048 μg Ciprofloxacin; 22°C
Figure 25

P. aeruginosa Log-Phase; PBS; pH 7.4; 40μg Cloxacillin; 22°C

Figure 26

P. aeruginosa Log-Phase; SS; pH 7.4; 512μg Cloxacillin; 22°C
Figure 27

P. aeruginosa Log-Phase; SS; pH 7.4; 1024µg Cloxacillin; 22°C

surviving fraction

minutes

Figure 28

P. aeruginosa Log-Phase; SS; pH 7.4; 2048µg Cloxacillin; 22°C

surviving fraction

minutes
Figure 29

Figure 30
Figure 33

P. aeruginosa Log-Phase; PBS; pH 7.4; 4096 µg Cloxacillin; 35°C

Figure 34

P. aeruginosa Log-Phase; SS; pH 7.4; 512 µg Cloxacillin; 35°C
Figure 35

P. aeruginosa Log-Phase; SS; pH 7.4; 1024 µg Cloxacillin; 35°C

Figure 36

P. aeruginosa Log-Phase; SS; pH 7.4; 2048 µg Cloxacillin; 35°C
Figure 37

Figure 38
Figure 39

Figure 40

P. aeruginosa Stat-Phase; SS; pH 7.4; 1024μg Clonazepam; 22°C

Surviving fraction vs. minutes
Figure 41

P. aeruginosa, Static Phase: SS, pH 7.4; 4096μg Ciprofloxacin, 22°C
The invention described herein was made in part by an employee of the United States Government and may be manufactured and used by and for the Government of the United States for governmental purposes without the payment of any royalties thereon of therefor.

FIELD OF INVENTION

The present invention relates to the field of pharmaceutical compounds and more particularly to physico-chemical alteration of macromolecular targets and target-accessibility to a drug or antitoxin resulting from inclusion of components of the Hofmeister series.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the non-substantial killing effect of a pH 5.5 PBS solution having 1024 µg/ml cloxacillin at 22° C. on a logarithmic-phase methicillin-resistant Staphylococcus aureus (MRSA) culture over a 20 minute period.

FIG. 2 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 512 µg/ml cloxacillin at 22° C. on a logarithmic-phase MRSA culture over a 20 minute period.

FIG. 3 illustrates the non-substantial killing effect of a pH 5.5 SS having 1024 µg/ml cloxacillin at 22° C. on a logarithmic-phase MRSA culture over a 20 minute period.

FIG. 4 illustrates the killing effect of a pH 7.4 SS having 512 µg/ml cloxacillin at 22° C. on a logarithmic-phase MRSA culture over a 60 minute period.

FIG. 5 illustrates the killing effect of a pH 7.4 SS having 512 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA culture over a 20 minute period.

FIG. 6 illustrates the killing effect of a pH 7.4 SS having 512 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 7 illustrates the killing effect of a pH 7.4 SS having 512 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 8 illustrates the killing effect of a pH 7.4 SS having 4096 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 9 illustrates the killing effect of a pH 7.4 SS having 4096 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 10 illustrates the killing effect of a pH 7.4 SS having 512 µg/ml cloxacillin at 35° C. on a logarithmic-phase MRSA culture over a 20 minute period.

FIG. 11 illustrates the killing effect of a pH 7.4 SS having 1024 µg/ml cloxacillin at 35° C. on a logarithmic-phase MRSA culture over a 20 minute period.

FIG. 12 illustrates the killing effect of a pH 7.4 SS having 2048 µg/ml cloxacillin at 35° C. on a logarithmic-phase MRSA culture over a 20 minute period.

FIG. 13 illustrates the killing effect of a pH 7.4 SS having 4096 µg/ml cloxacillin at 35° C. on a logarithmic-phase MRSA culture over a 20 minute period.

FIG. 14 illustrates the killing effect of a pH 7.4 SS having 512 µg/ml cloxacillin at 35° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 15 illustrates the killing effect of a pH 7.4 SS having 1024 µg/ml cloxacillin at 35° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 16 illustrates the killing effect of a pH 7.4 SS having 2048 µg/ml cloxacillin at 35° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 17 illustrates the killing effect of a pH 7.4 SS having 4096 µg/ml cloxacillin at 35° C. on a stationary-phase MRSA culture over a 60 minute period.

FIG. 18 illustrates the non-substantial killing effect of a pH 7.4 SS at 22° C. and 35° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 60 minute period.

FIG. 19 illustrates the non-substantial killing effect of a pH 7.4 SS at 22° C. and 35° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 60 minute period.

FIG. 20 illustrates the non-substantial killing effect of a pH 7.4 PBS solution at 22° C. and 35° C. on a stationary-phase Pseudomonas aeruginosa culture over a 60 minute period.

FIG. 21 illustrates the non-substantial killing effect of a pH 7.4 SS at 22° C. and 35° C. on a stationary-phase Pseudomonas aeruginosa culture over a 60 minute period.

FIG. 22 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 512 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 23 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 1024 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 24 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 2048 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 25 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 4096 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 26 illustrates the killing effect of a pH 7.4 SS having 512 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 27 illustrates the killing effect of a pH 7.4 SS having 1024 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 28 illustrates the killing effect of a pH 7.4 SS having 2048 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 29 illustrates the killing effect of a pH 7.4 SS having 4096 µg/ml cloxacillin at 22° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 30 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 512 µg/ml cloxacillin at 35° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 31 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 1024 µg/ml cloxacillin at 35° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 32 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 2048 µg/ml cloxacillin at 35° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.

FIG. 33 illustrates the non-substantial killing effect of a pH 7.4 PBS solution having 4096 µg/ml cloxacillin at 35° C. on a logarithmic-phase Pseudomonas aeruginosa culture over a 20 minute period.
As used herein, the term “humectant” refers to a substance that absorbs water, helps another substance retain moisture, and/or disrupts or affects the water activity of macromolecules. Humectants include compounds in the Hofmeister series, including, but not limited to chaotropes, kosmotropes, and astringents or styptics, such as alum, Burrow’s solution (i.e., aluminum acetate), and silver nitrate, which at concentrations of approximately 10 mM or less also acts as an anti-toxin and antiseptic.

As used herein, the term “penicillin” refers to any of a group of broad-spectrum antibiotic drugs of the central formula R--C18H12N2O4S, obtained from penicillin molds or produced synthetically, and which are most active against Pseudomonas aeruginosa. Penicillins are used in the treatment of various bacterial infections and diseases. Penicillins include, but are not limited to, methicillin, cloxacillin, amoxicillin, ampicillin, carbencillin, dicloxacillin, oxacillin, and therapeutic equivalents.

As used herein, the term “salt” refers to a chemical compound derived from an acid by replacing a hydrogen, wholly or partly, with a metal or an electropositive radical. This includes ionic products of Bronsted-Lowry acid-base reactions and ionic products of Lewis acids in water, i.e., conjugate bases, where both these forms of salts are found within the Hofmeister series.

As used herein, “SS” is an abbreviation for a salt solution for denaturing, i.e., altering the structure of, macromolecules, and which is comprised of compounds within the Hofmeister series.

As used herein, “PBS” is an abbreviation for non-denaturing phosphate buffered saline, a buffer solution commonly used to suspend and wash cells.

**BACKGROUND**

Both Gram-positive and Gram-negative pathogenic bacteria are causing significant health problems around the world due to these bacteria developing, or innately presenting, biochemical mechanisms that thwart medical management by various types of antibiotics. Effective use of penicillins, one major class of antibiotics, is particularly being threatened. For example, Gram-positive methicillin-resistant Staphylococcus aureus (MRSA) has become resistant to control by penicillins, and Pseudomonas aeruginosa, an opportunistic member of Gram-negative bacteria, is innately beyond control of penicillins.

One area of concern is hospital-acquired or nosocomial parenteral antibiotic-resistant bacterial infections from topical colonized bacteria or suppurating infections. These types of bacteria frequently escape sterilization efforts prior to invasive procedures allowing them to enter the body and establish infection.

The acquiring of penicillin resistance by bacteria is life-threatening and is being addressed by the pharmaceutical industry through the development of new generations of penicillins. The pharmaceutical industry largely directs its efforts to creating new molecular alterations of existing penicillins in order to circumvent continually evolving resistance that in turn defeats efficacy of such new penicillins. Each generation of penicillins successively targets penicillin-resistant mechanisms in the bacterial coat in a way designed to circumvent biochemical resistance mechanisms that have evolved within pathogenic bacteria to resist previous generations of penicillins. It is unlikely that this cycle of new biochemical specificity for penicillin activity, followed by evolving resistance to that specificity, will be therapeutically successful since the percentages of penicillin-resistant pathogenic variants that defeat antibiotic management is rapidly increasing.

Penicillins bind to penicillin-binding proteins (PBPs) in the bacterial coat, and especially in Gram-positive bacteria those targets tend to evolve into non-binding or non-accessible motifs where, for example, one binding motif is said to be a 4-amino acid sequence-serine-X-X-lysine-that provides covalent acylation of serine by the beta-lactam ring of penicillins. In Gram-negative bacteria, resistance to penicillins is additionally complicated by the presence of transporters in the coat-associated outer membrane that export the influx of penicillin, and by similarly located porins that can restrict uptake of penicillin. Therefore, it is important to resolve both the evolved resistance to binding of penicillin to amino acid target motifs and the blockage of uptake of penicillin into cells, which together largely account for observed antibiotic resistance.

It is known that covalent binding of penicillins to PBPs of actively replicating bacterial cells leads to defective coats, which ultimately cause cell lysis and death. It is known that this covalent binding is commonly defeated by evolution of structural alteration in PBPs during development of penicillin resistance.

In addition, penicillin transport mechanisms also require proteins of specific structure to perform the function of penicillin efflux. Structural alterations of these proteins by pH, salt concentration, or dehydration are often reversible. For example, for at least one strain of MRSA, penicillin resistance is observed at pH 7.4; however, penicillin sensitivity is returned when those bacteria are exposed to penicillin at pH 5.6. Conversely to physico-chemically induced reversible denaturation, covalent binding of penicillin to PBP targets is not reversible, but rather immutable whether achieved in growing or static bacterial cells.

It is desirable to have a system and method for killing topical bacteria known to be penicillin-resistant, particularly MRSA and Pseudomonas aeruginosa.
It is desirable to have a system and method for reversing the levels of penicillin-resistant bacterial infections that plague individuals in both community and hospital settings.

It is desirable to have a system and method for managing penicillin-resistance by mechanisms other than biochemical advances in the structure and/or activity of penicillin.

It is further desirable to have a system and method for altering in situ targets and inaccessibility of penicillin in bacteria by physico-chemical treatments, providing novel paradigms for effective topical applications of antibiotics and other drugs and anti-toxins.

**SUMMARY OF THE INVENTION**

The present invention is embodied as a pharmaceutical solution at pH 7.4 comprised of high concentrations of phosphate, sulfate, and acetate anions, potassium and ammonium cations, a trace of free ammonia, penicillin, and water. In an exemplary embodiment, the SS is applied within a range of temperatures, specifically 22°C and 35°C. The SS is capable of inducing alteration of bacterial in situ target proteins to create sensitivity of the bacteria to otherwise ineffective penicillins.

**DETAILED DESCRIPTION OF INVENTION**

For the purpose of promoting an understanding of the present invention, references are made in the text to exemplary embodiments of a system and method for the physico-chemical alteration of penicillin-binding proteins in penicillin-resistant Gram-positive and Gram-negative bacteria to induce sensitivity to otherwise ineffective penicillins, only one of which is described herein. It should be understood that no limitations on the scope of the invention are intended by describing these exemplary embodiments. One of ordinary skill in the art will readily appreciate that alternate but functionally equivalent use of compounds, solvents, concentrations, pH, and methods may be used to expand biochemical target reactivity and accessibility to reactive drugs and anti-toxins.

The inclusion of additional elements, such as drugs and anti-toxins, depending upon the specific biochemical targets and conditions involved, may be deemed readily apparent and obvious to one of ordinary skill in the art. Specific elements disclosed herein are not to be interpreted as limiting, but rather as a basis for the claims and as a representative basis for teaching one of ordinary skill in the art to employ the present invention.

Moreover, the terms “substantially” or “approximately” as used herein may be applied to modify any quantitative representation that could permissibly vary without resulting in a change in the basic function to which it is related.

The physico-chemical aspect of the SS, less penicillin, is conceived upon knowledge of water activity relative to biochemical macromolecular rearrangements, and the knowledge that temperature and pH also affect these rearrangements. The specifics of the SS, less penicillin, are taken from the extensive Hofmeister series for enhancing reversible denaturation of macromolecules in Gram-positive bacteria (e.g., methicillin-resistant *Staphylococcus aureus*) and Gram-negative bacteria (e.g., *Pseudomonas aeruginosa*). The Hofmeister series is comprised of compounds known to effect water activity and stability of a substantial and varied range of macromolecules. The physico-chemical conditions of reversible denaturation rearrange biological macromolecules, thereby altering target motifs in protein, inhibiting structure-specific protein activities, altering passive diffusion through structural barriers, and imposing a temporal static state upon many metabolic processes, thereby improving outcome from coincident therapeutic treatment of targets. That is, such a disrupted and static condition in bacteria can be used as an advantage by including one or more different drugs or anti-toxins in this denaturing solution; drugs and anti-toxins can include a range of known biochemical agents, such as penicillin, antiseptics, or disinfectants selected for compatibility with normal tissue at the site of topical application. In this embodiment, cloxacillin, an otherwise substantially ineffective penicillin, was chosen and proved to be highly efficient in directly killing bacteria normally resistant to penicillin.

FIGS. 1 through 41 illustrate the efficiency of a SS formulation derived from members of the Hofmeister series for physico-chemically inducing alteration of in situ target proteins to establish sensitivity of Gram-positive (i.e., MRSA) and Gram-negative bacteria (i.e., *Pseudomonas aeruginosa*) to otherwise ineffective penicillins.

The SS formulation at pH 7.4, but not pH 5.5, is effective in reversing penicillin-resistance in a methicillin-resistant strain of *Staphylococcus aureus* (MRSA) and in *Pseudomonas aeruginosa*, important bacterial pathogens. The SS affects water activity, which in turn alters the macromolecular structure of the target. In this manner, penicillin-resistant proteins are rearranged by physico-chemical conditions such that covalent binding of penicillins is allowed and the structures of penicillin transport proteins are altered or thereby inactivated to defeat the function of penicillin efflux.

In an exemplary embodiment for treatment of planktonic bacteria, the SS contains high, at times saturated, concentrations of phosphate, sulfate, and acetate anions, potassium and ammonium cations, plus a small concentration of free ammonia, all prepared in water, and applied at 22°C or 35°C. For example, in one embodiment, the molar concentrations of the phosphate, sulfate, and acetate anions may be 3.1 M, 0.4 M, and 0.2 M, respectively, and the potassium and ammonium cations may be 2.6 M and 3.7 M, respectively. In an exemplary embodiment, ammonium hydroxide is added to the SS in order to bring the SS to the desired pH (e.g., pH 7.4), resulting in a small amount of free ammonia. In various other embodiments, sulfuric acid, acetic acid, a combination thereof, or another acid is added to lower the pH of the SS. In various embodiments, each compound may have a molar concentration ranging from 0.01 M to 4.0 M. In addition, the SS may include any of the compounds in the Hofmeister series; the specific formula of the SS may be adjusted for maximal physico-chemical effectiveness in each specific application.

In various physico-chemical embodiments, the pH, concentrations, solvents and/or temperature of the formulations may vary in order to maximize the effectiveness of macromolecular rearrangements and the outcome for different pathological biomolecular targets, all with regard for the tolerance of the normal tissue involved in topical applications. For example, the temperature may range from freezing to 43°C, the limiting temperature for thermal pain sensation. In various embodiments, the solvent (i.e., water) may be blended with or replaced with a substance(s) that is known to affect water activity and macromolecular rearrangements, such as alcohols (e.g., ethanol, propanol, butanol) or aprotic solvents (e.g., dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide).

In an exemplary embodiment, the SS is prepared to an effective pH of 7.4. In various other embodiments, the SS may be prepared to a pH ranging from 3.5 to 10. The pH may be varied to maximize the effectiveness of the macromolecular rearrangements and the outcome for different pathological biomolecular targets.
In an exemplary embodiment, the SS formulation, often acting as a humectant, is dictated by the alteration of water activity that leads to reversible denaturation of biomolecules, both those that are targets and those affecting accessibility to targets, thereby maximizing the effectiveness of the macromolecular arrangements and the resulting outcome. In various embodiments, the formulation of SS may be varied by the addition of additives that affect the water activity of biomolecules. These additives are taken from the Hofmeister series, and include chaotropes and kosmotropes, including humectants characterized as astringents or styptics, such as alum, Burow’s solution (i.e., aluminum acetate), and silver nitrate. These additives are used to effect the reversible denaturation of biomolecules resulting in effective presentation of a variety of new biomolecular targets to drugs or anti-toxins, such as silver nitrate, contained within the topical solutions.

FIGS. 1 through 17 illustrate kill curve time course experiments of stationary and logarithmic-phase MRSA bacterial suspensions exposed to PBS as well as denaturing SS at pH 5.5 or pH 7.4 in the presence of cloxacillin concentrations spanning from 512 µg/ml to 4096 µg/ml. Experiments were conducted at 22° C or 35° C. The completion time for the experiments ranged from 20 minutes to 24 hours.

For these experiments, the MRSA strain was grown overnight in Mueller-Hinton broth (MH)+2% NaCl at 35° C, subcultured into fresh media, and grown to mid-logarithmic phase. The cells were centrifuged and resuspended in pH 7.4 MH+2% NaCl to produce an OD600 nm known to indicate logarithmic-phase or stationary-phase of growth. An appropriate volume of cells was added to 1 ml of buffered SS in a 10 ml Falcon tube to yield a final concentration of ca. 1x10^8 colony forming units (CFU)/ml. Survival was determined for bacteria held for varied exposure times of up to 24 hours in the SS or in PBS at pH 5.6 or pH 7.4, each altered with cloxacillin concentrations ranging in doublings from 512 µg/ml to 4096 µg/ml. Survival was measured from samples held at 22° C or 35° C. After exposure, samples of 50 µl were then withdrawn and a serial dilution series established. Cells were then plated on MH+2% NaCl agar plates and incubated at 22° C or 35° C for CFU formation, after which colonies were counted, surviving fractions recorded, and survival curves constructed. Triplicate experiments were conducted for each exposure condition. The cells were treated under static conditions in all cases and treatments were always made on cells held in salt solutions, never on cells held in growth media. In addition to logarithmic-phase cells, stationary-phase cells removed from growth cycle were also treated.

Cells exposed to SS at pH 7.4 in the presence of cloxacillin are killed. Killing is more efficient for logarithmic-phase cells than for stationary-phase cells. Both logarithmic-phase and stationary-phase cells are killed more effectively by treatment at 35° C. than treatment at 22° C.

Killing efficiency is evaluated as therapeutically sufficient according to the 10^-5 level of killing in 5 minutes specified by the British Standard BS EN 1276:1997 Chemical Disinfectants and Antiseptics, which is referred to as the gold standard for efficacy of bactericidal agents. Typically, agents meeting the British Standard are too toxic for human topical application. However, this is not a restriction for effective SS containing cloxacillin used in the illustrated embodiment.

As developed in FIGS. 1 through 4, substantial killing of static logarithmic-phase MRSA by cloxacillin is achieved at pH 7.4 at 22° C. For SS only, PBS at pH 5.5 or at pH 7.4 is not effective, and neither is SS at pH 5.5. Regarding the results shown in FIG. 4, no survivors were seen on any of the treated plates; therefore, the surviving fraction for all time points is less than the 2x10^-5 indicated as a conservative maximum allowed for the dilution factor plated. Experiments were also conducted on MRSA logarithmic-phase cells with SS alone at 22° C. No killing effect was seen at pH 5.6 or pH 7.4 for SS alone.

As FIGS. 5 through 9 illustrate, the efficiency of killing of stationary-phase MRSA cells at 22° C does not provide the 10^-5 level of killing in 5 minutes specified by the British Standard. However, at the highest concentration of cloxacillin, that is, 4096 µg/ml, the 10^-5 level of killing is achieved in 3 hours, as detailed in FIG. 9.

As shown in FIGS. 10 through 13, killing is enhanced by exposure of logarithmic-phase MRSA to cloxacillin at 35° C.

As FIGS. 14 through 17 illustrate, the enhanced killing extends to stationary cells exposed at 35° C as well. The efficiency of killing of both logarithmic and stationary-phase MRSA cells at 35° C approaches or exceeds the 10^-5 level of killing in 5 minutes specified by the British Standard.

The level of killing is concentration dependent and is based upon the conditions of the treatment, such as species and initial sensitivity/resistance, whether the cells are in a stationary or logarithmic growth phase, temperature, and specific Hofmeister series compounds used.

FIGS. 18 through 41 illustrate kill curve time-course experiments of stationary-phase and logarithmic-phase *Pseudomonas aeruginosa* bacterial suspensions exposed to PBS, to SS, or in the presence of cloxacillin concentrations spanning from 512 µg/ml to 4096 µg/ml. Experiments were conducted at both 22° C and 35° C. For these experiments, the *Pseudomonas aeruginosa* cells were first grown in trypticase soy broth and then frozen in aliquots, which were later rescued into MI broth+2% NaCl for use as in the MRSA experiments. An appropriate volume of cells was added to 1 ml of comparative salt solutions in a 10 ml Falcon tube to yield a final concentration of ca. 1x10^8 colony forming units (CFU)/ml. Survival was determined for bacteria held for varied exposure times of up to 60 minutes in PBS, in SS, in PBS altered with cloxacillin concentrations ranging in doublings from 512 µg/ml to 4096 µg/ml, or in SS containing cloxacillin concentrations ranging in doublings from 512 µg/ml to 4096 µg/ml. The salt solutions were compared at a pH of 5.6 or 7.4. Survival was measured from samples held at 22° C or 35° C. After exposure, samples of 50 µl were then withdrawn and a serial dilution series established. Cells were then plated on MI+2% NaCl agar plates and incubated at 22° C or 35° C for CFU formation, after which colonies were counted, surviving fractions recorded, and survival curves constructed. Triplicate experiments were conducted for each exposure condition. The cells were treated under static conditions in all cases and treatments were always made on cells held in salt solutions, never on cells held in growth media. In addition to logarithmic-phase cells, stationary-phase cells removed from growth cycle were also treated.

FIGS. 18 through 21 show the results of the control experiments. For the control experiments, logarithmic-phase *Pseudomonas aeruginosa* cells were treated in PBS (FIG. 18) or SS (FIG. 19), and stationary-phase *Pseudomonas aeruginosa* were treated in PBS (FIG. 20) or SS (FIG. 21). All experiments were conducted at both 22° C and 35° C for 60 minutes. No substantial killing was observed for any of these controls.
FIGS. 22 through 25 illustrate the non-substantial killing logarithmic-phase *Pseudomonas aeruginosa* using a PBS solution with cloxacillin concentrations ranging from 512 µg/ml to 4096 µg/ml at pH 7.4. The experiments were conducted at 22°C for 20 minutes.

FIGS. 26 through 29 illustrate the efficiency of killing logarithmic-phase *Pseudomonas aeruginosa* using SS with cloxacillin concentrations ranging from 512 µg/ml to 4096 µg/ml at pH 7.4. For cloxacillin concentrations of 2048 µg/ml and 4096 µg/ml, the experiments were conducted at 22°C for 20 minutes. For cloxacillin concentrations of 512 µg/ml and 1024 µg/ml, the experiments were conducted at 22°C for 10 minutes. At all concentrations of cloxacillin, the SS, but not the PBS solution, was substantially efficient in killing *Pseudomonas aeruginosa*.

FIGS. 30 through 33 illustrate the non-substantial killing of logarithmic-phase *Pseudomonas aeruginosa* using a PBS solution with cloxacillin concentrations ranging from 512 µg/ml to 4096 µg/ml at pH 7.4. The experiments were conducted at 32°C for 20 minutes.

FIGS. 34 through 37 illustrate the substantial killing of logarithmic-phase *Pseudomonas aeruginosa* using the SS with cloxacillin concentrations ranging from 512 µg/ml to 4096 µg/ml at pH 7.4. The experiments were conducted at 35°C for 20 minutes.

FIGS. 38 through 41 illustrate the substantial killing of stationary-phase *Pseudomonas aeruginosa* using SS with cloxacillin concentrations ranging from 512 µg/ml to 4096 µg/ml at pH 7.4. The experiments were conducted at 22°C for 20 minutes.

Killing is more efficient for cells exposed to higher concentrations of cloxacillin. In the embodiments shown, the highest concentration of cloxacillin tested was 4096 µg/ml; however, it is not necessarily the maximum effective or tolerated concentration. The concentration of cloxacillin or other drug may be varied depending on the contact effect required for topical applications in any given situation. That is, the preferred concentration should be determined for each specific application.

The use of various concentrations of compounds from the Hofmeister series can affect macromolecular hydration and protein denaturation, which may expose novel penicillin-binding amino acid motifs of PBPs and other non-specific proteins. In addition, high salt concentrations inactivate efflux transporters and porins. As a result, both penicillin-resistant Gram-positive and Gram-negative pathogenic bacteria may be created as penicillin-sensitive by physico-chemical denaturation induced by exposure to the embodied SS and related salt solutions when containing penicillin. It is expected that under these specific conditions, universal creation of protein target sensitivity to penicillin results from such physico-chemical treatment, that is, a field effect of covalent binding of proteins to penicillin is established during the physico-chemical treatment by SS in the presence of penicillin. This field effect, whereby any affected bacterial proteins may be modified to enhance penicillin-binding, promotes direct killing and allows, for the first time, the potential application of penicillin to control static cells, including stationary-phase cells, as well as actively growing cultures of bacteria. Penicillin dissolves well in the SS described and may be used for treatment in the form of a topical application.

Cloxacillin at relatively high concentration in the SS substantially kills static logarithmic-phase and static stationary-phase penicillin-resistant MRSA and *Pseudomonas aerugi- nosa* cells rapidly upon exposure at room temperature, and the degree of killing is advanced using variables of pH and temperature. This substantial killing of static penicillin-resis-
toxins may be applied in this regard. For example, in topical applications of the SS to fulminating fasciitis, a condition requiring rapid and multiple reversals of currently resistant pathologic processes, penicillin may be included to kill bacteria and silver ions may be included to inactivate superantigens.

The present embodiment claims management of water activity and structure associated with macromolecules in bacterial pathogens by use of compounds of the Hofmeister series, and examines the substantial killing effects due to new target motifs that react with penicillin in planktonic bacteria during exposures to the SS. Topical clinical applications of the SS carrying drugs and/or anti-toxins will, however, encounter sessile, as well as planktonic bacteria, the principal additional barrier to accessibility by drugs and/or anti-toxins then being the biofilm of polysaccharides, mucopeptides, etc. secreted by and covering the sessile bacteria. It is expected that dehydration and denaturation by humectant-like and other compounds from the Hofmeister series in the SS will permeabilize this highly hydrated biofilm to drugs and/or anti-toxins as well as expose new target motifs and inactivate outer membrane-associated accessibility barriers as shown in the embodiment herein.

What is claimed is:

1. A pharmaceutical composition comprising: a potassium cation; an ammonium cation; a sulfate anion; an acetate anion; and a penicillin; wherein said potassium cation, said ammonium cation, said sulfate anion, said acetate anion, and said penicillin are in a solution having a pH ranging from 3.5 to 10; wherein said solution has a temperature ranging from 0° C. to 43° C.; wherein each of said potassium cation, said ammonium cation, said sulfate anion, said acetate anion, and said penicillin has a molar concentration ranging from 0.01 M to 4.0 M and are of a concentration which induces alteration of in situ target proteins to establish sensitivity of bacteria to otherwise ineffective penicillins.
2. The pharmaceutical composition of claim 1 wherein said potassium cation has a molar concentration of 2.6 M.
3. The pharmaceutical composition of claim 1 wherein said ammonium cation has a molar concentration of 3.7 M.
4. The pharmaceutical composition of claim 1 wherein said sulfate anion has a molar concentration of 3.1 M.
5. The pharmaceutical composition of claim 1 wherein said acetate anion has a molar concentration of 0.4 M.
6. The pharmaceutical composition of claim 1 wherein said penicillin has a molar concentration of 0.2 M.
7. The pharmaceutical composition of claim 1 which further includes free ammonia.
8. The pharmaceutical composition of claim 1 wherein said solution is at 22° C.
9. The pharmaceutical composition of claim 1 wherein said solution is at 37° C.
10. The pharmaceutical composition solution of claim 1 wherein said bacteria are Gram-positive.
11. The pharmaceutical composition solution of claim 1 wherein said bacteria are methicillin-resistant Staphylococcus aureus (MRSA).
12. The pharmaceutical composition solution of claim 1 wherein said bacteria are Gram-negative.
13. The pharmaceutical composition solution of claim 1 wherein said bacteria are Pseudomonas aeruginosa.
14. The pharmaceutical composition solution of claim 1 wherein said penicillin is semi-synthetic penicillin.
15. The pharmaceutical composition solution of claim 1 wherein said penicillin is cloxacillin.
16. The pharmaceutical composition solution of claim 1 wherein said penicillin concentration is between 512 µg/mL and 4096 µg/mL.
17. A method of making a pharmaceutical composition comprising the steps of:
   providing a potassium cation, an ammonium cation, a phosphate anion, a sulfate anion, an acetate anion, a penicillin; and ammonium hydroxide; placing said potassium cation, said ammonium cation, said phosphate anion, said sulfate anion, said acetate anion into an aqueous solution in a proportional concentration which induces alteration of in situ target proteins to establish sensitivity of bacteria to otherwise ineffective penicillins; adding said penicillin to said solution; and using said ammonium hydroxide to bring said solution to a desired pH.
18. The method of claim 17 which further comprises the step of bringing said solution to a desired temperature.
19. The method of claim 18 wherein said desired temperature is 22° C.
20. The method of claim 18 wherein the desired temperature is 37° C.
21. The method of claim 17 wherein said composition is adapted for administration by topical application.
22. The method of claim 17 wherein said composition is adapted for administration by oral ingestion.
23. The method of claim 17 wherein said composition is adapted for administration by inhalation.
24. The method of claim 17 wherein said composition is adapted for administration by instillation.
25. The method of claim 17 wherein said bacteria are in a stationary growth phase.
26. The method of claim 17 wherein said bacteria are in a logarithmic growth phase.
27. The method of claim 17 wherein said bacteria are methicillin-resistant Staphylococcus aureus (MRSA).
28. The method of claim 17 wherein said bacteria are Pseudomonas aeruginosa.
29. The method of claim 17 wherein said penicillin is semi-synthetic penicillin.
30. The method of claim 29 wherein the penicillin is cloxacillin.
31. The method of claim 17 wherein said penicillin concentration is between 512 µg/mL and 4096 µg/mL.
32. The method of claim 17 wherein said potassium cation has a molar concentration of 2.6 M.
33. The method of claim 17 wherein said ammonium cation has a molar concentration of 3.7 M.
34. The method of claim 17 wherein said phosphate anion has a molar concentration of 3.1 M.
35. The method of claim 17 wherein said sulfate anion has a molar concentration of 0.4 M.
36. The method of claim 17 wherein said acetate anion has a molar concentration of 0.2 M.